Clinically relevant interpretation of solid phase assays for HLA antibody

Current Opinion in Organ Transplantation

Volumn 21, Issue 4, 2016, Pages 453-458

  Bettinotti, Maria P ^a   Zachary, Andrea A ^a   Leffell, Mary S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody mediated rejection; HLA epitopes; HLA specific antibodies; solid phase immunoassays

Indexed keywords

EPITOPE; HLA ANTIBODY; ALLOANTIBODY; HLA ANTIGEN;

ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; CELL BASED ASSAY; EPITOPE MAPPING; HLA MATCHING; HUMAN; IMMUNOASSAY; REVIEW; SOLID PHASE IMMUNOASSAY; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; PROCEDURES;

HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES;

EID: 84969625955     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000326     Document Type: Review

References (70)

1. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum Immunol 2009; 70:574-579.
2. Zachary AA, Leffell MS. Desensitization for solid organ and hematopoietic stem cell transplantation. Immunol Rev 2014; 258:183-207.
3. Zachary AA, Vega RM, Lucas DP, Leffell MS. HLA antibody detection and characterization by solid phase immunoassays: methods and pitfalls. Methods Mol Biol 2012; 882:289-308.
4. Gebel HM, Bray RA. HLA antibody detection with solid phase assays: great expectations or expectations too great? Am J Transplant 2014; 14:1964-1975.
5. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95:19-47.
6. Visentin J, Guidicelli G, Moreau JF, et al. Deciphering allogeneic antibody response against native and denatured HLA epitopes in organ transplantation. Eur J Immunol 2015; 45:2111-2121.
7. Gombos P, Opelz G, Scherer S, et al. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant 2013; 13:2075-2082.
8. Middleton D, Jones J, Lowe D. Defining HLA-specific antibodies. Am J Transplant 2014; 14:236.
9. Visentin J, Guidicelli G, Bachelet T, et al. Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation. Transplantation 2014; 98:738-744.
10. Tambur AR, Rosati J, Roitberg S, et al. Epitope analysis of HLA-DQ antigens: what does the antibody see? Transplantation 2014; 98:157-166.
11. Baxter-Lowe LA, Cecka M, Kamoun M, et al. Center-defined unacceptable HLA antigens facilitate transplants for sensitized patients in a multicenter kidney exchange program. Am J Transplant 2014; 14:1592-1598.
12. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol 2009; 70:496-501.
13. Schnaidt M, Weinstock C, Jurisic M, et al. HLA antibody specification using single-antigen beads-a technical solution for the prozone effect. Transplantation 2011; 92:510-515.
14. Tambur AR, Herrera ND, Haarberg KM, et al. Assessing antibody strength: comparison of MFI, C1q, and titer information. Am J Transplant 2015; 15:2421-2430.
15. Schwaiger E, Wahrmann M, Bond G, et al. Complement component C3 activation: the leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads. Transplantation 2014; 97:1279-1285.
16. Visentin J, Vigata M, Daburon S, et al. Deciphering complement interference in antihuman leukocyte antigen antibody detection with flow beads assays. Transplantation 2014; 98:625-631.
17. Locke JE, Zachary AA, Warren DS, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009; 9:2136-2139.
18. Leffell MS, Kim D, Vega RM, et al. Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation. Transplantation 2014; 97:525-533.
19. Zachary AA, Lucas DP, Montgomery RA, Leffell MS. Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation 2013; 95:701-704.
20. Crespo M, Heidt S, Redondo D, Pascual J. Monitoring B cell subsets and alloreactivity in kidney transplantation. Transplant Rev (Orlando) 2015; 29:45-52.
21. Chong AS, Sciammas R. Memory B cells in transplantation. Transplantation 2015; 99:21-28.
22. Lucas DP, Leffell MS, Zachary AA. Tetramer staining for the detection of HLA-specific B cells. Methods Mol Biol 2013; 1034:313-318.
23. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369:1215-1226.
24. Yell M, Muth BL, Kaufman DB, et al. C1q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection. Transplantation 2015; 99:1151-1155.
25. Loupy A, Legendre C. From mean fluorescence intensity to C1q-binding: the saga ofanti-HLA donor-specific antibodies. Transplantation 2015; 99:1107-1108.
26. Schaub S, Honger G, Koller MT, et al. Determinants of C1q binding in the single antigen bead assay. Transplantation 2014; 98:387-393.
27. Peacock S, Kosmoliaptsis V, Bradley AJ, Taylor CJ. Questioning the added value of Luminex single antigen beads to detect C1q binding donor HLA-specific antibodies. Transplantation 2014; 98:384-386.
28. Sicard A, Ducreux S, Rabeyrin M, et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol 2015; 26:457-467.
29. O'Leary JG, Kaneku H, Banuelos N, et al. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant 2015; 15:1003-1013.
30. Everly MJ, Rebellato LM, Haisch CE, et al. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation 2014; 97:494-501.
31. Valenzuela NM, McNamara JT, Reed EF. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant 2014; 19:33-40.
32. Duquesnoy RJ. HLA epitope based matching for transplantation. Transpl Immunol 2014; 31:1-6.
33. El-Awar N, Terasaki PI, Cai J, et al. Epitopes of HLA-A, B, C, DR, DQ, DP and MICA antigens. Clin Transpl 2009; 295-321.
34. Mallon DH, Bradley JA, Winn PJ, et al. Three-dimensional structural modelling and calculation of electrostatic potentials of HLA Bw4 and Bw6 epitopes to explain the molecular basis for alloantibody binding: toward predicting HLA antigenicity and immunogenicity. Transplantation 2015; 99:385-390.
35. Wiebe C, Nevins TE, Robiner WN, et al. The synergistic effect of class II HLA epitope-mismatch and nonadherence on acute rejection and graft survival. Am J Transplant 2015; 15:2197-2202.
36. Kosmoliaptsis V, Gjorgjimajkoska O, Sharples LD, et al. Impact of donor mismatches atindividual HLA-A,-B,-C,-DR, and-DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation. Kidney Int 2014; 86:1039-1048.
37. Lucas DP, Leffell MS, Zachary AA. Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response. Transplantation 2015; 99:77-85.
38. Glotz D, Tambur A. Stratifying patients based on epitope mismatching: ready for primetime? Am J Transplant 2015; 15:2021-2022.
39. Duquesnoy RJ, Kamoun M, Baxter-Lowe LA, et al. Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant 2015; 15:923-930.
40. Cecka JM, Reed EF, Zachary AA. HLA high-resolution typing for sensitized patients: a solution in search of a problem? Am J Transplant 2015; 15:855-856.
41. Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant 2014; 14:255-271.
42. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14:272-283.
43. Devos JM, Gaber AO, Teeter LD, et al. Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection. Transplantation 2014; 97:534-540.
44. Kim JJ, Balasubramanian R, Michaelides G, et al. The clinical spectrum of de novo donor-specific antibodies in pediatric renal transplant recipients. Am J Transplant 2014; 14:2350-2358.
45. Tagliamacco A, Cioni M, Comoli P, et al. DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant. Transpl Int 2014; 27:667-673.
46. Loupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol 2015; 26:1721-1731.
47. Aubert O, Bories MC, Suberbielle C, et al. Risk of antibody-mediated rejection in kidney transplant recipients with anti-HLA-C donor-specific antibodies. Am J Transplant 2014; 14:1439-1445.
48. Bachelet T, Martinez C, Del Bello A, et al. Deleterious impact of donor-specific anti-HLA antibodies toward HLA-Cw and HLA-DP in kidney transplantation. Transplantation 2016; 100:159-166.
49. Cippa PE, Gaspert A, Etter C, et al. Late antibody-mediated rejection by de novo donor HLA-DP-specific antibody after renal transplantation: a case report. Hum Immunol 2014; 75:462-465.
50. Mierzejewska B, Schroder PM, Baum CE, et al. Early acute antibody-mediated rejection of a negative flow crossmatch 3rd kidney transplant with exclusive disparity at HLA-DP. Hum Immunol 2014; 75:703-708.
51. Starling RC, Stehlik J, Baran DA, et al. Multicenter analysis of immune biomarkers and heart transplant outcomes: results of the clinical trials in organ transplantation-05 study. Am J Transplant 2016; 16:121-136.
52. Frank R, Molina MR, Goldberg LR, et al. Circulating donor-specific anti-human leukocyte antigen antibodies and complement C4d deposition are associated with the development of cardiac allograft vasculopathy. Am J Clin Pathol 2014; 142:809-815.
53. Tran A, Fixler D, Huang R, et al. Donor-specific HLA alloantibodies: impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation. J Heart Lung Transplant 2016; 35:87-91.
54. Colvin MM, Cook JL, Chang P, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation 2015; 131:1608-1639.
55. Reinsmoen NL, Lai CH, Mirocha J, et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation 2014; 97:595-601.
56. Kauke T, Kneidinger N, Martin B, et al. Bronchiolitis obliterans syndrome due to donor-specific HLA-antibodies. Tissue Antigens 2015; 86:178-185.
57. Morrell MR, Pilewski JM, Gries CJ, et al. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant 2014; 33:1288-1294.
58. Safavi S, Robinson DR, Soresi S, et al. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2014; 33:1273-1281.
59. Gerlach UA, Lachmann N, Sawitzki B, et al. Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation. Transpl Int 2014; 27:280-289.
60. Kubal C, Mangus R, Saxena R, et al. Prospective monitoring of donor-specific anti-HLA antibodies after intestine/multivisceral transplantation: significance of de novo antibodies. Transplantation 2015; 99:e49-e56.
61. Del Bello A, Congy-Jolivet N, Danjoux M, et al. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int 2015; 28:1371-1382.
62. Del Bello A, Congy-Jolivet N, Muscari F, et al. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014; 14:867-875.
63. Del Bello A, Congy-Jolivet N, Rostaing L, Kamar N. Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors. J Hepatol 2014; 61:963-965.
64. Grabhorn E, Binder TM, Obrecht D, et al. Long-term clinical relevance of de novo donor-specific antibodies after pediatric liver transplantation. Transplantation 2015; 99:1876-1881.
65. Iacob S, Cicinnati VR, Lindemann M, et al. Donor-specific anti-HLA antibodies and endothelial C4d deposition-association with chronic liver allograft failure. Transplantation 2015; 99:1869-1875.
66. O'Leary JG, Kaneku H, Demetris AJ, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014; 20:218-227.
67. Hayde N, Broin PO, Bao Y, et al. Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. Kidney Int 2014; 86:600-609.
68. Suviolahti E, Ge S, Nast CC, et al. Genes associated with antibody-dependent cell activation are overexpressed in renal biopsies from patients with antibody-mediated rejection. Transpl Immunol 2015; 32:9-17.
69. Vitalone MJ, Sigdel TK, Salomonis N, et al. Transcriptional perturbations in graft rejection. Transplantation 2015; 99:1882-1893.
70. Xu Z, Nayak D, Yang W, et al. Dysregulated microRNA expression and chronic lung allograft rejection in recipients with antibodies to donor HLA. Am J Transplant 2015; 15:1933-1947.